*/
Lev Gerlovin, Ezra Josephson | Life Sciences
Let’s say interchangeability is a viable regulatory option for manufacturers of biosimilars. Would it always make sense to seek an interchangeability designation from a strategic perspective? Because of the diversity and complexity of product and manufacturer characteristics, there may not be a single optimal strategy, but rather a continuum. Click below to read the article.
The science of credibility: Communicating complex science to diverse stakeholders
Effective delivery depends on whether the audience perceives both the message and its source as credible. CRA recently hosted a forum to discuss the importance...